Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients

References

• Weingart SN, Brown E, Bach PB, et al. NCCN task force report: oral chemotherapy. J Natl Compr Canc Netw 2008;6(Suppl 3):S1-S14
   PubMedGoogle Scholar
• Revlimid [package insert]. Celgene Corporation; Summi, NJ: November 2013
   Google Scholar
• Ujjani C, Cheson BD. The current status and future impact of targeted therapies in non-hodgkin lymphoma. Expert Rev Hematol 2013;6(2):191-203
   PubMed Web of Science ®Google Scholar
• Zolinza [package insert]. Merck; Whitehouse Station, NJ: October 2012
   Google Scholar
• Zydelig (idelalisib) [prescribing information]. Gilead Sciences; Foster City, CA: July 2014
   Google Scholar
• Imbruvica (ibrutinib) [prescribing information]. Pharmacyclics Inc; Sunnyvale, CA: 2014
   Google Scholar
• Zortress (everolimus) [prescribing information]. Novartis Pharmaceuticals; East Hanover, NJ: February 2013
   Google Scholar
• Intlekofer A, Younes A. From empiric to mechanism-based therapy for peripheral T-cell lymphoma. Int J Hematol 2014;99(3):249-62
   PubMedGoogle Scholar
• Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2006;55:117-42
   Google Scholar
• Beijnen J, Schellens J. Drug interactions in oncology. Lancet Oncology 2004;5(8):489-96
   PubMed Web of Science ®Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nature Reviews Cancer 2006;6:546-59
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Goodman & Gilman’s the pharmacological basis of therapeutics. 10th edition. McGraw-Hill; New York: 2001. pp. 3-29
   Google Scholar
• Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health Syst Pharm 2007;64:S15-24
   PubMed Web of Science ®Google Scholar
• Lipitor [package insert]. Parke-Davis; New York, NY: 2014
   Google Scholar
• Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions: a comprehensive review of the literature. J Oncol Pract 2014;10(4):e255-68
   PubMedGoogle Scholar
• Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 2014;23(1):22-35
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487-97
   PubMed Web of Science ®Google Scholar
• Timmers L, Boons CC, Kropff F, et al. Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncol 2014;53(2):259-67
   PubMed Web of Science ®Google Scholar
• Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993;11(6):1189-97
   PubMed Web of Science ®Google Scholar
• Regnier Denois V, Poirson J, Nourissat A, et al. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care (Engl) 2011;20(4):520-7
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25(6):481-96
   PubMed Web of Science ®Google Scholar
• Esper P. Identifying strategies to optimize care with oral cancer therapy. Clin J Oncol Nurs 2013;17(6):629-36
   PubMed Web of Science ®Google Scholar
• Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011;86(6):471-4
   PubMed Web of Science ®Google Scholar
• Moon JH, Sohn SK, Kim SN, et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 2012;29(2):1179-85
   PubMedGoogle Scholar
• Klein CE, Kastrissios H, Miller AA, et al. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a cancer and leukemia group B study. Cancer Chemother Pharmacol 2006;57(2):199-206
   PubMed Web of Science ®Google Scholar
• Lee CR, Nicholson PW, Souhami RL, Deshmukh AA. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992;10(6):1007-13
   PubMed Web of Science ®Google Scholar
• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59(1):56-66
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304(1):10-15
   PubMed Web of Science ®Google Scholar
• Wu EQ, Guerin A, Yu AP, et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010;26(12):2861-9
   PubMed Web of Science ®Google Scholar
• Rudd P, Byyny RL, Zachary V, et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989;46(2):169-76
   PubMed Web of Science ®Google Scholar
• Weingart SN, Spencer J, Buia S, et al. Medication safety of five oral chemotherapies: a proactive risk assessment. J Oncol Pract 2011;7(1):2-6
   PubMedGoogle Scholar
• Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94(9):652-61
   PubMed Web of Science ®Google Scholar
• Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. Clin Lymphoma Myeloma Leuk 2012;12(4):223-9
   PubMed Web of Science ®Google Scholar
• St. Charles M, Bollu V, Hornyak E, et al. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2209
   Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15(6):e22-33
   PubMed Web of Science ®Google Scholar
• McCue DA, Lohr LK, Pick AM. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy 2014;34(5):481-94
   PubMed Web of Science ®Google Scholar
• Possidente CJ, Bucci KK, McClain WJ. Motivational interviewing: a tool to improve medication adherence? Am J Health Syst Pharm 2005;62(12):1311-14
   PubMedGoogle Scholar
• Touchette DR, Shapiro NL. Medication compliance, adherence, and persistence: current status of behaviral and educational interventions to improve outcomes. Journal Managed Care Pharmacy 2008;14(6 Suppl):s2-s10
   PubMedGoogle Scholar
• D’Amato S. Improving patient adherence with oral cheotherapy. Oncology Issues 2008;42-5
   Google Scholar
• Boyle D, bubalo J. Enhancing patient adherence to improve outcomes with oral chemotherapy. US Pharmacist 2007;32:1-8
   Google Scholar
• Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. Semin Oncol Nurs 2011;27(2):133-41
   PubMedGoogle Scholar
• Doucette WR, Farris KB, Youland KM, et al. Development of the drug adherence work-up (DRAW) tool. J Am Pharm Assoc 2003 2012;52(6):e199-204
   Google Scholar
• Griffin E. Safety considerations and safe handling of oral chemotherapy agents. Clin J Oncol Nurs 2003;7(6 Suppl):25-9
   PubMedGoogle Scholar
• Connor TH, McDiarmid MA. Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 2006;56(6):354-65
   PubMed Web of Science ®Google Scholar
• Held K, Ryan R, Champion JM, et al. Caregiver survey results related to handling of oral chemotherapy for pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2013;35(6):e249-53
   Google Scholar
• Goodin S, Griffith N, Chen B, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract 2011;7(1):7-12
   PubMedGoogle Scholar